Search | Clinical Trials Finder

Conditions: Healthy Volunteers
Interventions: Inhaled BGF (PT010) Dose 1, Inhaled BGF (PT010) Dose 2, Inhaled BGF (PT010) Dose 3, Inhaled GFF (PT003), Inhaled Symbicort Dose 1, Inhaled Symbicort Dose 2; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Aclidinium/formoterol 400/12μg, Formoterol; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Asthma
Interventions: GP MDI, BFF MDI, Placebo MDI; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: Bakersfield, California • Lancaster, California • Long Beach, California + 12 more

Conditions: COPD
Interventions: Glycopyrronium and Formoterol Fumarate (GFF) Dose 1, Glycopyrronium and Formoterol Fumarate (GFF) Dose 2, Glycopyrronium (GP) Dose 1, Glycopyrronium (GP) Dose 2; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: GFF MDI (PT003), GP MDI (PT001), FF MDI (PT005), Placebo; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 113
States / cities: Birmingham, Alabama • Florence, Alabama • Jasper, Alabama + 110 more

Conditions: Chronic Obstructive Pulmonary Disease, COPD, Chronic Bronchitis, Emphysema
Interventions: formoterol fumarate; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: COPD Patients
Interventions: Symbicort, Formoterol turbohaler, Placebo for Symbicort pMDI, Placebo for Formoterol Turbohaler; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 95 Years
Enrollment: 2,026 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 224
States / cities: Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 107 more

Conditions: Alzheimer's Disease, Cognitive Dysfunction
Interventions: Formoterol A, Formoterol B (placebo); Drug · Other
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 50 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Asthma
Interventions: SKP FlutiForm HFA pMDI; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 10
States / cities: Scottsdale, Arizona • Orange County, California • Colorado Springs, Colorado + 7 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BGF, MITT; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 22,369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Asthma
Interventions: BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF pMDI 320/9 μg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 2,274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 107
States / cities: Saraland, Alabama • Phoenix, Arizona • Sun City West, Arizona + 96 more

Conditions: Asthma
Interventions: arformoterol, levalbuterol; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 14
States / cities: Beverly Hills, California • Orange, California • Savannah, Georgia + 10 more

Conditions: Asthma
Interventions: Formoterol Fumarate; Drug
Lead sponsor: Dey; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 2
States / cities: Denver, Colorado • Medford, Oregon

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 229
States / cities: Athens, Alabama • Cullman, Alabama • Fairhope, Alabama + 189 more

Conditions: Asthma
Interventions: Formoterol Fumarate; Drug
Lead sponsor: Dey; Industry
Eligibility: 5 Years to 12 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 12
States / cities: Little Rock, Arkansas • Long Beach, California • Mission Viejo, California + 9 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BGF; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 3,402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Asthma
Interventions: BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF pMDI 320/9 μg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 2,187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 88
States / cities: Chandler, Arizona • Tempe, Arizona • Tucson, Arizona + 78 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Asthma
Interventions: formoterol; Device
Lead sponsor: Novartis; Industry
Eligibility: 5 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 12
States / cities: Huntington Beach, California • San Diego, California • San Jose, California + 8 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Arformoterol tartrate, Placebo: Normal Saline, Treadmill Exercise, Cycle Exercise; Drug · Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Asthma
Interventions: Budesonide/formoterol pMDI, Budesonide HFA pMDI; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 46
States / cities: Muscle Shoals, Alabama • Little Rock, Arkansas • Anaheim, California + 43 more

Conditions: Asthma
Interventions: Budesonide, Budesonide-Formoterol; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 12 Years to 120 Years
Enrollment: 66,581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COPD Exacerbation
Interventions: Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic); Drug
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 40 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: GFF MDI, GP MDI, FF MDI, Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®), Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 2,103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 121
States / cities: Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more

Search by objective public record fields.

Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers

Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

PK Study of PT003 and PT001 in Japanese Healthy Subjects

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease

Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease

A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005

A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects

Study in Patients With Asthma

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Study in Patients With Asthma

EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma

Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD

A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects

Replication of the D58 Asthma Trial in Healthcare Claims Data

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)